Imapextide, a once-weekly GLP-1 receptor antagonist designed to treat dangerously low blood sugar after weight-loss surgery, was well tolerated in healthy volunteers with pharmacokinetics supporting weekly dosing.
~90-hour half-lifeImapextide's mean elimination half-life, enabling convenient once-weekly subcutaneous dosing for post-bariatric hypoglycemia treatment
What the researchers found
In this Phase 1 trial, 69 healthy volunteers received imapextide at various doses (10-200 mg single dose; 10-30 mg weekly for 4 weeks) or placebo. The drug demonstrated dose-proportional exposure with a median time to peak concentration of 24-48 hours and a mean half-life of approximately 90 hours, supporting once-weekly administration.
The most common side effects were injection site reactions (erythema and swelling). During mixed meal tolerance tests, imapextide increased GLP-1 concentrations at early time points and slightly accelerated gastric emptying. Drug-drug interaction studies showed minimal, non-clinically relevant interaction with rosuvastatin. These findings support further development for post-bariatric hypoglycemia treatment.
Why it matters
Post-bariatric hypoglycemia is a serious complication of weight-loss surgery that currently has no approved drug treatment — patients rely mainly on dietary changes and glucose monitoring. As bariatric surgery becomes more common, the need for effective pharmacotherapy grows. Imapextide represents a novel approach: rather than adding more GLP-1 activity (as most peptide drugs do), it blocks it, addressing the excessive insulin release that causes dangerous blood sugar drops.
How the study worked
This was a 3-part, double-blind, placebo-controlled Phase 1 study in healthy adults. Part 1 (single ascending dose) tested subcutaneous imapextide at 10-200 mg. Part 2 (multiple ascending dose) tested 10-30 mg weekly for 4 doses. Part 3 assessed drug-drug interactions. Participants were randomized 3:1 to imapextide or placebo. Safety, pharmacokinetics, and pharmacodynamic responses during mixed meal tolerance tests were measured.
What this study cannot tell us
This study was conducted in healthy volunteers, not in patients with post-bariatric hypoglycemia, so the therapeutic efficacy for the target condition remains unproven. Effects on glycemic parameters during meal tests were variable, and the study was not powered to assess clinical efficacy. The sample size was small (69 total across all cohorts). Longer-term safety data beyond 4 weekly doses is not yet available.
How to read the evidence
This is a Phase 1, double-blind, placebo-controlled trial — the first step in clinical drug development. While the study design is rigorous for its purpose (safety and pharmacokinetics), it was conducted in healthy volunteers, not patients with the target condition, and cannot demonstrate therapeutic efficacy.
When this study was published
Published in 2025, this is a very recent Phase 1 trial representing the earliest clinical stage of a novel peptide therapeutic. Phase 2 efficacy trials in post-bariatric hypoglycemia patients would be expected to follow.
The bigger picture
While the GLP-1 drug landscape is dominated by agonists for diabetes and obesity, imapextide takes the opposite approach — blocking GLP-1 receptors. This highlights that the same pathway can cause problems in different directions: too little GLP-1 activity contributes to diabetes, while excessive GLP-1 signaling after bariatric surgery can cause dangerous hypoglycemia. This antagonist approach fills a gap in the peptide therapeutics toolkit.
Questions still open
- Will imapextide effectively prevent hypoglycemic episodes in patients with post-bariatric hypoglycemia in Phase 2 trials?
- Could GLP-1 receptor antagonism have unintended effects on appetite, weight, or glucose homeostasis with chronic use?
- Are there other conditions involving excessive GLP-1 signaling that could benefit from this antagonist approach?
Common questions
What is post-bariatric hypoglycemia and why is it a problem?
Why block GLP-1 when so many drugs try to activate it?
Read the original research
Sustained Action of Imapextide, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.
The Journal of clinical endocrinology and metabolism
Citation
Fabbrini, Elisa; Koshkina, Anastasiya; Hackett, Michael; Zhao, Michael; Thalluri, Kishore; Hompesch, Marcus; Macias, Alejandra; Schneider, Kristi; D'Alessio, David A; DiMarchi, Richard D; Azoulay, Salomon. (2025). Sustained Action of Imapextide, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/clinem/dgaf691